A Guide To The Risks Of Investing In Inozyme Pharma Inc. (INZY)


In a filing, Inozyme Pharma Inc. revealed its SVP, COO Bjarke Henric Bjorn acquired Company’s shares for reported $29885.0 on Dec 15. In the deal valued at $1.39 per share,21,500 shares were bought. As a result of this transaction, Bjarke Henric Bjorn now holds 105,441 shares worth roughly $ 0.29 million.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Then, Longitude Capital Partners III bought 1,355,000 shares, generating $4,999,950 in total proceeds. Upon buying the shares at $3.69, the 10% Owner now owns 4,174,379 shares.

Before that, Pivotal bioVenture Partners Fu bought 1,070,000 shares. Inozyme Pharma Inc. shares valued at $3,948,300 were divested by the Director at a price of $3.69 per share. As a result of the transaction, Pivotal bioVenture Partners Fu now holds 2,661,154 shares, worth roughly $7.42 million.

Jefferies initiated its Inozyme Pharma Inc. [INZY] rating to a Hold in a research note published on Friday, May 26, 2022; the price target was $5. PT values the company’s stock at a premium of 44.2 to its Friday closing price. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early February with a ‘”a Buy”‘ rating. Needham began covering INZY with “Buy” recommendation on November 29, 2021. Wedbush started covering the stock on August 18, 2020. It rated INZY as “an Outperform”.

Price Performance Review of INZY

On Friday, Inozyme Pharma Inc. [NASDAQ:INZY] saw its stock fall -4.78% to $2.79. On the same session, the stock had its day’s lowest price of $2.7196, but rose to a high of $2.97. Over the last five days, the stock has gained 3.33%. Inozyme Pharma Inc. shares have risen nearly 165.71% since the year began. Nevertheless, the stocks have fallen -53.19% over the past one year. While a 52-week high of $6.25 was reached on 02/16/23, a 52-week low of $0.99 was recorded on 01/03/23. SMA at 50 days reached $1.94, while 200 days put it at $2.89. A total of 0.66 million shares were traded, compared to the trading of 1.27 million shares in the previous session.

Levels Of Support And Resistance For INZY Stock

The 24-hour chart illustrates a support level at 2.68, which if violated will result in even more drops to 2.58. On the upside, there is a resistance level at 2.93. A further resistance level may holdings at 3.08. The Relative Strength Index (RSI) on the 14-day chart is 61.43, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.25, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 41.96%. Stochastics %K at 64.57% indicates the stock is a holding.

How much short interest is there in Inozyme Pharma Inc.?

A steep rise in short interest was recorded in Inozyme Pharma Inc. stocks on Jan 30, 2023, growing by 1.28 million shares to a total of 1.57 million shares. Yahoo Finance data shows the prior-month short interest on Dec 29, 2022 was 0.29 million shares. There was a rise of 81.55%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 5.80% of the overall stock float, the days-to-cover ratio (short ratio) rose to 5.55.

Inozyme Pharma Inc. [INZY] – Who Are The Largest Shareholders?

In filings from Deep Track Capital LP, it is revealed that the company now owns 3,250,000 shares, or roughly 8.05% of the outstanding INZY shares. Additionally, Adage Capital Management LP increased 19.39% of its stake after which the total value it holdings stand at $7,502,334, while Rock Springs Capital Management L added 9.92% of its stake to hold $7.47 million in the firm. Over the last quarter, CHI Advisors LLC purchased 208,599 shares of Inozyme Pharma Inc., while Sphera Funds Management Ltd. bought 450,000 shares. At present, The Vanguard Group, Inc. is holding 1,333,206 shares valued at $3.23 million. Affinity Asset Advisors LLC owned 500,000 shares of the company at the time of its most recent 13F filing, worth $1.21 million.

According to FactSet, Inozyme Pharma Inc.’s share price will average $22.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 582.59 percent from its previous closing price of $2.93. Analysts expect Inozyme Pharma Inc. stock to reach the higher price of $40.00, while the lowest price estimate is $12.00. However, 6 analysts have rated INZY stock as a Buy in their predictions for 2023. The most recent change occurred on August 18, 2020 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $40 price target.


Please enter your comment!
Please enter your name here